GRACE :: Lung Cancer
GRACE Video

SBRT for Oligometastatic Lung Cancer

Share
download as a pdf file Download PDF of this page
GRACE Cancer Video Library - Lung

GCVL_LU-F10_SBRT_Oligometastatic_Lung_Cancer

 

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines oligometastatic lung cancer and describes the recent trend toward the use of stereotactic body radiation therapy to treat it.

Download Transcript

How Did You Like This Video?

Please feel free to offer comments and raise questions in our Discussion Forums.

 

Transcript

First, let’s define the term “oligometastatic disease.” Oligometastatic disease typically means patients who have metastatic disease, but have a few metastases that, if they could be eradicated, their life could be prolonged. There are some good examples of the literature where patients have been resected, let’s say for metastatic colorectal cancer, or metastatic renal cancer, let’s say they had a brain metastasis that was resected and given curative therapy for their primary cancer, and there is about a 20-25% overall survival rate in that situation.

That, broadened out with the development of stereotactic body radiation therapy, has brought into play SBRT for patients with oligometastases for a variety of tumors. There is some recent literature in lung cancer, let’s say, that show that if you have patients with a few metastases that are receiving systemic therapy, that you can achieve median survivals approaching 20 months in metastatic lung cancer, and that’s previously unseen. That data was a trial from UT Southwestern and the University of Colorado groups, published this past year in the JCO — one of the most cited papers in the JCO this past year.

I think the oligometastatic patient population is a good patient population for focused radiation therapy. People ask, “what is oligometastasis?” It has classically been defined as patients with three or fewer metastases who have their remainder of the disease or the disease burden is under control with  systemic therapy; some have expanded that to five or six metastases. It typically doesn’t matter where they are. The classic example, of course, is a metastasis to the brain. We’ve applied this to patients in the lung, liver, spine, various places that are able to receive this focused radiation dose, and I think it’s a good tool, if chosen for the right patients, to extend their survival — perhaps we could even cure a few.


Comments are closed.

Ask Us, Q&A
Lung/Thoracic Cancer Expert Content

Archives

Share
download as a pdf file Download PDF of this page

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share
download as a pdf file Download PDF of this page

Join the GRACE Faculty

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share
download as a pdf file Download PDF of this page

Subscribe to the GRACEcast Podcast on iTunes

Share
download as a pdf file Download PDF of this page

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share
download as a pdf file Download PDF of this page

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243